Integrin alpha 5 beta 1

Integrin alpha 5 beta 1

Integrin alpha 5 beta 1 Informations sur la molécule

Molecule Name
Integrin alpha-5/beta-1
Alias de la molécule
Integrin alpha 5 beta 1,ITGA5&ITGB1
Drug Development Progress
Nombre de médicaments cliniques4
Nombre de médicaments commercialisés1
Phase de R&D la plus avancéeApproved
Alias de la cible
Integrin alpha5beta1
Contexte de la molécule
Integrin alpha 5 beta 1 / Integrin α5β1, which is a major cellular receptor for the extracellular matrix protein fibronectin and plays a fundamental role during mammalian development., is composed of α5 (ITGA5/CD49e) and β1 (ITGB1/CD29) subunits. Integrins are adhesion receptors that transmit bidirectional signals across the plasma membrane. The Integrin alpha 5 beta 1 and its primary extracellular matrix ligand fibronectin (Fn) are of great biological importance.

Integrin alpha 5 beta 1 Liste de produits

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
RisuteganibALG-1001; AM011; AM-011(Allegro Ophthalmics)Phase 1 ClinicalAllegro Ophthalmics Llc
Diabetic macular oedema; Diabetic Retinopathy; Geographic Atrophy; Macular Degeneration
Details
Pegylated recombinant human endostatin (Tsinghua University)M-2ES; CRB-0401Phase 1 ClinicalBeijing Proji Pharmaceutical Technology Co Ltd, Beijing Protgen Biotechnology Development Co Ltd, Tsinghua University
Carcinoma, Non-Small-Cell Lung; Neoplasms; Pancreatic Neoplasms; Solid tumours
Details
VAX-014VAX-014Phase 1 ClinicalVaxiion Therapeutics Llc
Solid tumours
Details
Integrin α5β1 therapy (Eli Lilly and Company)Phase 1 ClinicalEli Lilly And Company
Cardiovascular Diseases
Details

Informations sur les médicaments commercialisés

Nom anglaisCode de recherchePhase de R&DEntreprisePlus ancien nom de marquePays d'approbation le plus ancienIndication la plus ancienneSociété d'approbation la plus ancienneDate d'approbation la plus ancienneIndicationEssai clinique
Recombinant human endostatin (Simcere)YH-16ApprovedJiangsu Simcere Pharmaceutical Co LtdEndostar, 恩度, EnduMainland ChinaCarcinoma, Non-Small-Cell LungShandong Xiansheng Zaiming Biopharmaceutical Co Ltd2005-09-12
Ascites; Brain metastases; Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Head and Neck Neoplasms; Nasopharyngeal Carcinoma; Osteosarcoma; Pleural Effusion, Malignant
Details